Vir Bio

Dr. Marianne De Backer, President and CEO of Vir Bio (NSDQ: VIR), joins Nasdaq's Kristina Ayanian to reflect on a milestone decade since the company's founding and a defining year of momentum — including new clinical data across two active programs and a major pharma collaboration. From Phase 1 results in their T-cell engager prostate cancer program to a strategic partnership with Astellas, De Backer shares how Vir Bio is advancing a differentiated pipeline while working to reshape the treatment landscape for chronic hepatitis delta. As the company moves closer to commercialization, she outlines what investors and the Nasdaq community should be watching in Vir Bio's next chapter.